Zymeworks Q2 FY26 net loss widens to $45 million; revenue guidance rises to $278 million-$292 million for FY26
Bitget2026/09/28 10:00- Zymeworks reported a GAAP net loss of USD 45 million for the quarter ended June 30, 2026, versus net income of USD 2.3 million a year earlier.
- First-half 2026 GAAP net loss widened to USD 89.2 million from USD 20.3 million in the prior-year period.
- Updated 2026 outlook calls for revenue of USD 278 million to USD 292 million following the Theravance Biopharma acquisition.
- Theravance deal adds YUPELRI profit-share cash flows; first-half 2026 YUPELRI sales were USD 133.1 million, generating USD 38.4 million collaboration revenue.
- Zymeworks expects 2026 adjusted EBITDA of USD 114 million to USD 128 million and plans to retain the existing commercial team supporting YUPELRI hospital promotion.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CNN Enters Generative AI Partnership with Google
US Stock Market Movement | Nvidia-backed AI pharmaceutical company Iambic Therapeutics (IAM.US) debuts on Nasdaq, surging over 11% after opening
As of press time, the stock is up more than 11%, trading at $17.77.
US Stock Market Movement | 3D Printing Materials Supplier Amaero (AMRO.US) Debuts on US Stock Market, Trading Halt Triggered After Opening
Amaero, a manufacturer specializing in titanium and refractory metal powders for 3D printing in the defense and aerospace sectors, has gone public on the US stock market.
Crypto prices
More
